ArticleBlood cancer journal2021

Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes.

Konstantinos Liapis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.